Protara Therapeutics TARA Stock
Protara Therapeutics Price Chart
Protara Therapeutics TARA Financial and Trading Overview
| Protara Therapeutics stock price | 4 USD |
| Previous Close | 3.92 USD |
| Open | 3.94 USD |
| Bid | 2.83 USD x 200 |
| Ask | 4.97 USD x 200 |
| Day's Range | 3.87 - 3.98 USD |
| 52 Week Range | 2.97 - 7.82 USD |
| Volume | 111.46K USD |
| Avg. Volume | 702.24K USD |
| Market Cap | 222.01M USD |
| Beta (5Y Monthly) | 1.494 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.36 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.57 USD |
TARA Valuation Measures
| Enterprise Value | 87.59M USD |
| Trailing P/E | N/A |
| Forward P/E | -2.4021795 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.2002431 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -1.257 |
Trading Information
Protara Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.494 |
| 52-Week Change | 24.05% |
| S&P500 52-Week Change | 18.32% |
| 52 Week High | 7.82 USD |
| 52 Week Low | 2.97 USD |
| 50-Day Moving Average | 4.17 USD |
| 200-Day Moving Average | 5.28 USD |
TARA Share Statistics
| Avg. Volume (3 month) | 702.24K USD |
| Avg. Daily Volume (10-Days) | 395.28K USD |
| Shares Outstanding | 56.2M |
| Float | 49.16M |
| Short Ratio | 5.96 |
| % Held by Insiders | 2.42% |
| % Held by Institutions | 81.06% |
| Shares Short | 4.54M |
| Short % of Float | 8.22% |
| Short % of Shares Outstanding | 8.08% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:40 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -24.29% |
| Return on Equity (ttm) | -37.27% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -69685000 USD |
| Net Income Avi to Common (ttm) | -63307000 USD |
| Diluted EPS (ttm) | -1.36 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 135.79M USD |
| Total Cash Per Share (mrq) | 2.42 USD |
| Total Debt (mrq) | 3.06M USD |
| Total Debt/Equity (mrq) | 1.69 USD |
| Current Ratio (mrq) | 15.691 |
| Book Value Per Share (mrq) | 3.291 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -62995000 USD |
| Levered Free Cash Flow (ttm) | -39341752 USD |
Profile of Protara Therapeutics
| Country | United States |
| State | NY |
| City | New York |
| Address | 345 Park Avenue South |
| ZIP | 10010 |
| Phone | 646 844 0337 |
| Website | https://www.protaratx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 46 |
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
Q&A For Protara Therapeutics Stock
What is a current TARA stock price?
Protara Therapeutics TARA stock price today per share is 4 USD.
How to purchase Protara Therapeutics stock?
You can buy TARA shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Protara Therapeutics?
The stock symbol or ticker of Protara Therapeutics is TARA.
Which industry does the Protara Therapeutics company belong to?
The Protara Therapeutics industry is Biotechnology.
How many shares does Protara Therapeutics have in circulation?
The max supply of Protara Therapeutics shares is 56.2M.
What is Protara Therapeutics Price to Earnings Ratio (PE Ratio)?
Protara Therapeutics PE Ratio is now.
What was Protara Therapeutics earnings per share over the trailing 12 months (TTM)?
Protara Therapeutics EPS is -1.36 USD over the trailing 12 months.
Which sector does the Protara Therapeutics company belong to?
The Protara Therapeutics sector is Healthcare.
Protara Therapeutics TARA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26363.44 USD — |
-0.83
|
8.24B USD — | 26348.51 USD — | 26739 USD — | — - | 8.24B USD — |
|
US Tech Global Market Composite
NQGM
US
|
2293.41 USD — |
-0.55
|
— — | 2289.02 USD — | 2320.36 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1268.04 USD — |
+0.34
|
— — | 1260.71 USD — | 1278.44 USD — | — - | — — |
|
US Tech Capital Market Composite
RCMP
US
|
140.4 USD — |
-0.63
|
— — | 140.31 USD — | 142.62 USD — | — - | — — |
- {{ link.label }} {{link}}
